Jul 9 2012
ImaCor
Inc., the pioneer of the world's only hemodynamic transesophageal
echocardiography (hTEE™)
management device, today released the Zura EVO™ ultrasound system. This
next-generation imaging platform is used with ImaCor's miniaturized,
disposable ClariTEE®
probe.
hTEE
technology includes a purpose-built ultrasound imaging system consisting
of the ClariTEE probe and Zura™ platform. The ClariTEE has a unique
piezoelectric design with a highly efficient structure to provide
quality imaging at 7 MHz with 15 cm penetration. Featuring optimized
signal processing, thermal management, and Adaptaflex™,
the ClariTEE probe on the Zura system provides real-time visualization
of the heart for up to 72 hours indwelling. This capability makes hTEE
technology ideal for hemodynamic management of critically ill or injured
patients over a period of time.
The new Zura EVO imaging system combines all of the intuitive
components of the current Zura platform in an ergonomically compact
design with a large touch screen. Additional new user-friendly features
include an enhanced hTEE measurement package specific to area changes of
the superior vena cava, and the right and left ventricles of the heart.
The Zura EVO incorporates ImaCor's newly released software, which
includes enhanced Auto-Q for optimal image quality and resolution.
"My department started the use of hTEE technology early this
year," commented Jukka Takala, MD, PhD, Professor of
Intensive Care Medicine and Director of
the Department of Intensive Care Medicine at University
Hospital Bern in Switzerland. "We were impressed with the ease of
learning to use this new monitoring technology, even by intensive care
specialists without prior echocardiography experience. Already
the earlier version of the hTEE technology proved very helpful in
patient management - we look forward with excitement to gain experience
with the improved new platform."
"Our company imperative to provide the future in critical care
monitoring is realized again today through the global release of the
Zura EVO," said Peter Pellerito, President/CEO. "The EVO and ClariTEE
probe are unlike conventional ultrasound in that they are built for
critical care workflow, bringing direct visualization and image
monitoring to intensivists. This enables hemodynamic management
capabilities that reduce cost and improve quality of care."